Literature DB >> 22534863

Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.

Kaoru Nagato1, Shinichiro Motohashi, Fumihiro Ishibashi, Kohsuke Okita, Kazuki Yamasaki, Yasumitsu Moriya, Hidehisa Hoshino, Shigetoshi Yoshida, Hideki Hanaoka, Shin-Ichiro Fujii, Masaru Taniguchi, Ichiro Yoshino, Toshinori Nakayama.   

Abstract

PURPOSE: The intravenous administration of α-Galactosylceramide (α-GalCer)-pulsed antigen presenting cells (APCs) is well tolerated and the increased IFN-γ producing cells in the peripheral blood after the treatment appeared to be associated with prolonged survival. An exploratory study protocol was designed with the preoperative administration of α-GalCer-pulsed APCs to clarify the mechanisms of these findings, while especially focusing on the precise tumor site.
METHODS: Patients with operable advanced lung cancer received an intravenous injection of α-GalCer-pulsed APCs before surgery. The resected lung and tumor infiltrating lymphocytes (TILs) as well as peripheral blood mononuclear cells were collected and the invariant NKT (iNKT) cell-specific immune responses were analyzed.
RESULTS: Four patients completed the study protocol. We observed a significant increase in iNKT cell numbers in the TILs and augmented IFN-γ production by the α-GalCer-stimulated TILs.
CONCLUSION: The administration of α-GalCer-pulsed APCs successfully induced the dramatic infiltration and activation of iNKT cells in the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22534863     DOI: 10.1007/s10875-012-9697-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  33 in total

1.  A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.

Authors:  Shinichiro Motohashi; Aki Ishikawa; Eiichi Ishikawa; Mizuto Otsuji; Toshihiko Iizasa; Hideki Hanaoka; Naomi Shimizu; Shigetoshi Horiguchi; Yoshitaka Okamoto; Shin-ichiro Fujii; Masaru Taniguchi; Takehiko Fujisawa; Toshinori Nakayama
Journal:  Clin Cancer Res       Date:  2006-10-06       Impact factor: 12.531

2.  Preserved IFN-alpha production of circulating Valpha24 NKT cells in primary lung cancer patients.

Authors:  Shinichiro Motohashi; Seiichiro Kobayashi; Toshihiro Ito; Kumiko K Magara; Osamu Mikuni; Noriaki Kamada; Toshihiko Iizasa; Toshinori Nakayama; Takehiko Fujisawa; Masaru Taniguchi
Journal:  Int J Cancer       Date:  2002-11-10       Impact factor: 7.396

3.  Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.

Authors:  Eiichi Ishikawa; Shinichiro Motohashi; Aki Ishikawa; Toshihiro Ito; Tetsuro Uchida; Takaaki Kaneko; Yuriko Tanaka; Shigetoshi Horiguchi; Yoshitaka Okamoto; Takehiko Fujisawa; Koji Tsuboi; Masaru Taniguchi; Akira Matsumura; Toshinori Nakayama
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

Review 4.  Invariant natural killer T cell-based immunotherapy for cancer.

Authors:  Shinichiro Motohashi; Toshinori Nakayama
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

5.  Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.

Authors:  Tomás Alvaro; Marylène Lejeune; Ma Teresa Salvadó; Ramón Bosch; Juan F García; Joaquín Jaén; Alison H Banham; Giovanna Roncador; Carlos Montalbán; Miguel A Piris
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

6.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

7.  A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.

Authors:  Aki Ishikawa; Shinichiro Motohashi; Eiichi Ishikawa; Hiroki Fuchida; Kazuko Higashino; Mizuto Otsuji; Toshihiko Iizasa; Toshinori Nakayama; Masaru Taniguchi; Takehiko Fujisawa
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

8.  Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load.

Authors:  Johan W Molling; Wendy Kölgen; Hans J J van der Vliet; Martijn F Boomsma; Hinke Kruizenga; Carolien H Smorenburg; Barbara G Molenkamp; Johannes A Langendijk; C René Leemans; B Mary E von Blomberg; Rik J Scheper; Alfons J M van den Eertwegh
Journal:  Int J Cancer       Date:  2005-08-10       Impact factor: 7.396

9.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  34 in total

Review 1.  Lipid antigens in immunity.

Authors:  C Marie Dowds; Sabin-Christin Kornell; Richard S Blumberg; Sebastian Zeissig
Journal:  Biol Chem       Date:  2014-01       Impact factor: 3.915

Review 2.  T-cell-associated cellular immunotherapy for lung cancer.

Authors:  Ke Li; Qing Zhang; Yang Zhang; Jie Yang; Junnian Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-08       Impact factor: 4.553

Review 3.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

4.  Maturation and upregulation of functions of murine dendritic cells (DCs) under the influence of purified aromatic-turmerone (AR).

Authors:  Tan Yonggang; Meng Yiming; Zhang Heying; Sun Cheng; Wang Qiushi; Yang Xianghong; Zheng Wei; Zhou Huawei; Fengping Shan
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

5.  A semisynthetic carbohydrate-lipid vaccine that protects against S. pneumoniae in mice.

Authors:  Marco Cavallari; Pierre Stallforth; Artem Kalinichenko; Dominea C K Rathwell; Thomas M A Gronewold; Alexander Adibekian; Lucia Mori; Regine Landmann; Peter H Seeberger; Gennaro De Libero
Journal:  Nat Chem Biol       Date:  2014-10-05       Impact factor: 15.040

6.  Natural killer T cell based Immunotherapy.

Authors:  Priyanka B Subrahmanyam; Wenji Sun; James E East; Junxin Li; Tonya J Webb
Journal:  J Vaccines Vaccin       Date:  2012-08-23

7.  Frequency and proliferative response of circulating invariant natural killer T cells in pediatric patients with malignant solid tumors.

Authors:  Tomoro Hishiki; Naoko Mise; Kazuaki Harada; Fumie Ihara; Mariko Takami; Takeshi Saito; Keita Terui; Mitsuyuki Nakata; Shugo Komatsu; Hideo Yoshida; Shinichiro Motohashi
Journal:  Pediatr Surg Int       Date:  2017-10-10       Impact factor: 1.827

8.  Invariant natural killer T infiltration in neuroblastoma with favorable outcome.

Authors:  Tomoro Hishiki; Naoko Mise; Kazuaki Harada; Fumie Ihara; Mariko Takami; Takeshi Saito; Keita Terui; Mitsuyuki Nakata; Shugo Komatsu; Hideo Yoshida; Shinichiro Motohashi
Journal:  Pediatr Surg Int       Date:  2017-10-10       Impact factor: 1.827

Review 9.  The regulatory role of invariant NKT cells in tumor immunity.

Authors:  Rosanna M McEwen-Smith; Mariolina Salio; Vincenzo Cerundolo
Journal:  Cancer Immunol Res       Date:  2015-05       Impact factor: 11.151

Review 10.  Targeting Natural Killer T Cells in Solid Malignancies.

Authors:  Zewde Ingram; Shriya Madan; Jenoy Merchant; Zakiya Carter; Zen Gordon; Gregory Carey; Tonya J Webb
Journal:  Cells       Date:  2021-05-27       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.